Phaseline

Targets › CD16

CD16: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on CD16, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Masonic Cancer Center, University of MinnesotaGTB-3650
Tri-specific killer engager (TriKE) targeting CD16 on NK cells, IL-15 co-stimulation, and
CD16, IL15, CD33Phase 1Myeloid MalignancyMar 2027

Conditions

Myeloid Malignancy (1)

Modalities

small molecule (1)

Companies

Masonic Cancer Center, University of Minnesota (1)

Related targets

IL15 (1) CD33 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.